Does Wegovy Decrease Libido — and What Might Actually Be Behind It?

What the clinical trial data and official guidance actually say

The STEP 1 trial (published in the New England Journal of Medicine and the foundation of Wegovy's UK licence) tracked side effects rigorously across nearly 2,000 adults over 68 weeks. Decreased libido did not emerge as a statistically notable finding in that data. The NHS medicines page for semaglutide lists the known side effects of Wegovy; reduced sex drive is absent from both the common and uncommon categories. The medicine's Summary of Product Characteristics, the document prescribers consult, mirrors this. So if you arrived here expecting a clear clinical signal that semaglutide suppresses libido, the honest answer is: the evidence does not support that conclusion. What it does support is a more complicated story, one where body weight, hormones, mood, side effect burden and relationship with food all shift at once, and teasing apart cause and effect is genuinely difficult. Reading about whether Wegovy can increase libido gives you the other side of that picture, because the research on this question cuts both ways.

How weight loss itself changes sex drive, and why that matters here

Significant weight loss alters hormone levels, energy, self-perception and cardiovascular fitness. In people with obesity, testosterone and oestrogen balance can shift as fat tissue is reduced; sleep quality often improves as weight falls; and conditions like obstructive sleep apnoea, which can flatten libido considerably, frequently improve too. These changes tend to support rather than suppress sex drive over time. But the early phase of treatment is different. The appetite-reducing effect of Wegovy is powerful in the first weeks, and the GI side effects that accompany it (nausea, fatigue, occasional vomiting) are real. When you feel genuinely unwell after eating, sexual interest understandably recedes. This is a temporary, situational response to physical discomfort, not a pharmacological action of semaglutide on the brain's reward or hormonal pathways. Most people find that once their body adjusts to the current dose, energy returns and with it the rest of ordinary life. If you are wondering whether increasing your Wegovy dose actually leads to greater weight loss, that context is useful for making sense of the adjustment period each step brings.

Mood, mental health and the indirect routes to libido change

Mood and libido are tightly linked. Some people starting a new weight-management treatment carry anxiety about whether it will work, worry about side effects, or are managing the psychological weight of a long struggle with their body. Any of those things can dampen sex drive independently of the medicine. Conversely, early progress (clothes fitting differently, more energy by mid-morning) can lift mood noticeably. The prescriber who reviews your treatment through a service like our clinician-led team at nume will look at the whole picture, not just the number on the scale. There is also a specific consideration for women: for those on oral contraceptives, the consultation process routinely covers the fact that tirzepatide (a different medicine, Mounjaro) can reduce pill absorption, whereas no equivalent absorption interaction has been established for semaglutide. HRT, contraception and any concurrent medication are all part of the clinical review. If a change in libido coincides with moving to a higher Wegovy dose, that timing is worth mentioning to your prescriber, because a brief step back in dose is sometimes clinically appropriate while your body catches up.

When to raise it, and with whom

A brief dip in libido during the first few weeks of Wegovy is not unusual and is almost always explained by the GI adjustment period rather than a direct drug effect. Persistent change (say, still present after six to eight weeks at a stable dose) is worth discussing with the prescriber reviewing your treatment. They can look at whether the dose titration pace suits you, whether any other medicines you take are relevant, and whether a blood test to check hormone levels makes sense. You can also report any unexpected side effect through the MHRA Yellow Card scheme; this is how regulators track signals that post-trial data begins to reveal. The right place to start, though, is a conversation, not a decision made late on a Wednesday night after reading a forum thread. That is the kind of question our prescribers hear most weeks, and it has a sensible clinical answer more often than not.